Ang II inhibition has been widely and successfully used to treat hypertension in patients with both reduced and preserved ejection fraction (EF), but angiotensin‐converting enzyme inhibitors and Ang II receptor blockers have failed to reduce mortality in hypertensive HFpEF patients [4, 10]. This evidence concerns the gene AGT and hypertensive disorder.